Positive currency fluctuations – driven by a strong American dollar – have helped lift the medtech company’s top line in the first quarter of financial 2021/2022, where the company’s revenue beat expectations.
It is therefore completely reasonable for Coloplast to raise its growth guidance a tad in Danish kroner in its report, says Søren Løntoft Hansen, senior equity analyst at Danish bank Sydbank.
According to the report, Coloplast’s organic growth was also over the market’s estimates.
More from MedWatch
In 2015, Genmab partnered with relatively unknown biotech firm Biontech. Reflecting on how far Genmab has come since, CEO Jan van de Winkel is still confident that partnerships, rather than acquisitions, are the way forward. If it had acquired Biontech at the time, the CEO speculates Genmab may have put a stop to other activities – including the Covid-19 vaccine efforts that went on to save millions of lives. This and fairness are worth remembering as biotech firms are increasingly strapped for cash, van de Winkel reflects.